Summary (tl;dr)

Clascoterone is trending due to promising Phase III clinical trial results for its 5% topical solution in treating male pattern hair loss, a potential breakthrough in a field with limited new treatments, alongside recent European marketing authorization for its 1% cream (Winlevi) for acne.

Essential Background

Clascoterone, sold under the brand name Winlevi, is a "first-in-class" topical antiandrogen medication. It works by blocking androgen receptors, which are involved in processes like sebum (oil) production and inflammation, key factors in acne development. It was first approved by the U.S. Food and Drug Administration (FDA) in August 2020 for the topical treatment of acne vulgaris in individuals aged 12 and older, marking the first FDA-approved acne drug with a new mechanism of action in nearly 40 years.

The Full Story

Clascoterone is currently trending due to two significant recent developments. Firstly, Cosmo Pharmaceuticals N.V. announced breakthrough topline results from two Phase III trials (SCALP 1 and SCALP 2) evaluating its 5% topical solution of clascoterone for male androgenetic alopecia (AGA), or male-pattern hair loss. These trials, conducted across the United States and Europe, enrolled 1,465 men and demonstrated statistically significant improvements in hair growth compared to a placebo, with one study showing a 539% relative improvement in target-area hair count. The company plans parallel regulatory submissions in the United States and Europe for this hair loss treatment after completing a 12-month safety follow-up in spring 2026.

Secondly, Cosmo Pharmaceuticals, along with Glenmark Pharmaceuticals, recently secured European Commission marketing authorization for Winlevi (clascoterone 10 mg/g cream) to treat acne vulgaris in 17 countries. However, this follows a negative opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in April 2025 regarding Winlevi's marketing authorization for adolescents (12 to 17 years of age), which Cosmo Pharmaceuticals intends to appeal. Meanwhile, Winlevi was also recently introduced in the UK, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in February 2025.

Why It Matters

The strong Phase III results for clascoterone 5% solution in male-pattern hair loss are highly significant, as the drug could become the first new therapeutic mechanism for this condition in over 30 years. Male androgenetic alopecia affects 1.2 billion to 2 billion men worldwide, and current treatments often have limitations such as systemic side effects or variable efficacy. Clascoterone's localized action, blocking androgen receptors directly at the hair follicle with minimal systemic absorption, could offer a safer and more appealing option for patients concerned about hormonal effects associated with oral treatments.

The European Commission's marketing authorization for Winlevi for acne further expands the reach of this "first-in-class" topical acne treatment, providing a novel option for patients in numerous European countries. Despite the CHMP's negative opinion on its use in adolescents, which the company is appealing, clascoterone has shown a positive post-marketing experience in the U.S. across both adult and adolescent populations since its 2020 FDA approval. These combined developments highlight clascoterone's potential as a versatile dermatological treatment for both acne and hair loss, addressing significant unmet needs in both areas.

Geographic Location

• Dublin, Ireland (Cosmo Pharmaceuticals N.V. announced breakthrough Phase III results for clascoterone 5% topical solution for male hair loss and the European Commission marketing authorization for Winlevi)
• Zurich, Zurich Canton, Switzerland (Cosmo Pharmaceuticals N.V. shares surged after the hair-loss treatment data announcement)
• United States (Regulatory submissions for clascoterone 5% topical solution for male androgenetic alopecia are underway; Winlevi, clascoterone 1% cream, was previously approved by the FDA in 2020 for acne vulgaris)
• European Union (European Commission marketing authorization for Winlevi (clascoterone 10 mg/g cream) in 17 countries for acne vulgaris; negative CHMP opinion on Winlevi for adolescents)
• United Kingdom (Clascoterone cream 1% (Winlevi®) approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and introduced in February 2025)
• Canada (Winlevi approved for medical use in 2023)
• Australia (Winlevi approved for medical use in 2024)
• New Zealand (Winlevi approved for medical use in 2024)